GENE-THERAPEUTIC DNA-VECTOR BASED ON THE GENE-THERAPEUTIC DNA-VECTOR VTVAF17, CARRYING THE TARGET GENE SELECTED FROM THE SOD1, SOD2, SOD3, CAT GENE GROUP TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, METHOD FOR PRODUCTION AND USE THEREOF, ESCHERICHIA COLI SCS110-AF/VTVAF17-SOD1 STRAIN, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-SOD2, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-SOD3, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-CAT, CARRYING A GENE-THERAPEUTIC DNA VECTOR, A METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR Russian patent published in 2020 - IPC C12N15/12 C12N15/70 C12N1/21 A61K48/00 C12R1/19 

FIELD: genetic engineering.

SUBSTANCE: invention can be used in biotechnology, medicine and agriculture for creation of gene therapy preparations. What is presented is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17, carrying a target gene selected from a group of genes SOD1, SOD2, SOD3, CAT to increase the level of expression of this target gene in the human body and animals. Gene-therapy DNA vector VTvaf17-SOD1, or VTvaf17-SOD2, or VTvaf17-SOD3, or VTvaf17-CAT has a nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4 respectively .Invention also discloses a method of producing said vector, use of a vector, an Escherichia coli strain carrying said vector, as well as a method of producing said vector on an industrial scale.

EFFECT: invention provides the possibility of its safe application for genetic therapy of humans and animals.

14 cl, 15 dwg, 20 ex